1. Introduction

Mitochondria are essential components of eukaryotic cells and are commonly described as the major sites of aerobic energy production. Through oxidative phosphorylation, mitochondria convert energy stored in nutrients into adenosine triphosphate (ATP), which supports cellular activities ranging from ion transport and protein synthesis to muscle contraction and neuronal signaling.

The functions of mitochondria extend considerably beyond energy production. Mitochondria participate in calcium regulation, apoptosis, reactive oxygen species signaling, lipid metabolism, amino-acid metabolism, cellular differentiation, and immune responses. Consequently, mitochondrial abnormalities can affect multiple physiological systems simultaneously.

Mitochondrial dysfunction refers to a state in which mitochondrial structure, bioenergetic activity, quality control, or signaling becomes impaired. Such dysfunction may arise from genetic mutations, aging, oxidative damage, metabolic stress, environmental exposure, inflammation, or impaired mitochondrial quality-control mechanisms.

The relationship between mitochondrial dysfunction and disease is particularly evident in metabolic and neurodegenerative disorders. Metabolic tissues such as skeletal muscle, liver, adipose tissue, and pancreatic β-cells depend heavily on mitochondrial function to regulate nutrient utilization and energy balance. Neurons are also highly dependent on mitochondrial ATP production because maintenance of membrane potentials and synaptic activity requires substantial energy.

Mitochondrial dysfunction may therefore represent both a cause and consequence of chronic disease. Metabolic abnormalities can damage mitochondria, while impaired mitochondria can further disrupt metabolism, creating a self-reinforcing pathological cycle.

This review examines the molecular mechanisms of mitochondrial dysfunction and evaluates its role in metabolic and neurodegenerative disorders. Particular emphasis is placed on oxidative stress, mitochondrial DNA damage, electron transport chain abnormalities, mitochondrial dynamics, mitophagy, calcium signaling, and therapeutic strategies.

2. Structure and Functions of Mitochondria

Mitochondria possess a distinctive double-membrane structure consisting of an outer mitochondrial membrane, an intermembrane space, an inner mitochondrial membrane, and the mitochondrial matrix.

The outer membrane regulates interactions between mitochondria and the cytoplasm, whereas the inner membrane contains the electron transport chain and ATP synthase.

The inner mitochondrial membrane is highly folded into structures known as cristae. These folds increase the surface area available for oxidative phosphorylation and are important for efficient ATP generation.

The mitochondrial matrix contains enzymes involved in the tricarboxylic acid cycle, fatty-acid oxidation, and other metabolic pathways.

Mitochondria also contain their own circular genome. Mitochondrial DNA encodes several proteins required for oxidative phosphorylation as well as ribosomal and transfer RNAs necessary for mitochondrial protein synthesis.

Mitochondrial function depends on coordinated expression of mitochondrial and nuclear genomes. Disruption of this interaction can impair respiratory-chain activity and mitochondrial homeostasis.

3. Oxidative Phosphorylation and ATP Production

Oxidative phosphorylation is the principal mechanism by which mitochondria generate ATP under aerobic conditions.

Electrons derived from nutrients are transferred through the electron transport chain, which consists of several major protein complexes located within the inner mitochondrial membrane.

The electron transport chain establishes a proton gradient across the inner mitochondrial membrane. ATP synthase uses this electrochemical gradient to generate ATP from adenosine diphosphate and inorganic phosphate.

Efficient oxidative phosphorylation is therefore essential for energy-intensive tissues.

However, electron transport is not completely efficient. A small proportion of electrons can interact with molecular oxygen to produce reactive oxygen species.

Under physiological conditions, these reactive oxygen species participate in cellular signaling. Excessive production, however, can produce oxidative stress and damage cellular components.

4. Mechanisms of Mitochondrial Dysfunction

Electron Transport Chain Dysfunction

Defects in respiratory-chain complexes can reduce ATP production and increase reactive oxygen species generation.

Complex I and complex III are particularly important sources of electron leakage under certain pathological conditions.

Reduced respiratory efficiency can force cells to rely more heavily on glycolysis and alter metabolic signaling.

Persistent electron transport chain dysfunction can therefore contribute to cellular energy deficiency and oxidative injury.

Mitochondrial DNA Damage

Mitochondrial DNA is vulnerable to oxidative damage because of its proximity to the electron transport chain and its limited protective mechanisms compared with nuclear DNA.

Mitochondrial DNA mutations can impair proteins required for oxidative phosphorylation.

Accumulation of mitochondrial DNA damage may therefore create a cycle in which defective respiration produces additional oxidative stress, which causes further mitochondrial damage.

This mechanism is particularly relevant to aging and neurodegeneration.

Oxidative Stress

Reactive oxygen species are continuously produced during mitochondrial metabolism.

When antioxidant defenses are sufficient, reactive oxygen species remain within a physiological range.

However, excessive mitochondrial ROS can damage:

• Proteins
• Lipids
• Nuclear DNA
• Mitochondrial DNA
• Membranes
• Respiratory-chain components

Mitochondrial oxidative stress can also activate inflammatory signaling pathways and promote cell death.

Mitochondrial Dynamics

Mitochondria are dynamic organelles that continuously undergo fusion and fission.

Fusion allows mitochondria to exchange components and may help maintain mitochondrial function.

Fission facilitates mitochondrial distribution and enables damaged mitochondrial fragments to be removed through mitophagy.

Excessive fission has been associated with mitochondrial fragmentation and dysfunction, whereas impaired fission can interfere with mitochondrial quality control.

Proteins such as dynamin-related protein 1, mitofusins, and optic atrophy protein 1 are important regulators of mitochondrial dynamics.

5. Mitophagy and Mitochondrial Quality Control

Mitophagy is a selective form of autophagy responsible for removing damaged mitochondria.

Efficient mitophagy prevents dysfunctional mitochondria from accumulating within cells.

The PINK1–Parkin pathway is one of the best-characterized mechanisms involved in mitochondrial quality control.

When mitochondrial membrane potential is disrupted, PINK1 can accumulate on the mitochondrial surface and facilitate recruitment of Parkin, promoting ubiquitination of mitochondrial proteins and subsequent autophagic removal.

Defective mitophagy can lead to accumulation of damaged mitochondria, increased ROS production, impaired ATP generation, and cellular stress.

Impaired mitochondrial quality control has been particularly associated with neurodegenerative diseases.

6. Mitochondrial Biogenesis

Mitochondrial biogenesis is the process through which cells increase mitochondrial content.

A major regulator of mitochondrial biogenesis is peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α).

PGC-1α interacts with transcription factors involved in mitochondrial gene expression and stimulates production of proteins required for oxidative metabolism.

AMP-activated protein kinase and sirtuin signaling can also influence mitochondrial biogenesis.

Reduced mitochondrial biogenesis can limit cellular capacity to replace damaged mitochondria and may contribute to metabolic dysfunction and aging.

7. Mitochondrial Dysfunction in Obesity

Obesity is associated with chronic inflammation, altered lipid metabolism, insulin resistance, and oxidative stress.

Mitochondrial dysfunction in adipose tissue can impair fatty-acid oxidation and increase the accumulation of metabolic intermediates.

Excess nutrient availability can place considerable metabolic pressure on mitochondria.

Adipose-tissue mitochondrial abnormalities can also promote inflammatory signaling and alter adipokine production.

In skeletal muscle, impaired mitochondrial oxidative capacity may contribute to reduced metabolic flexibility and insulin resistance.

Thus, mitochondrial dysfunction may participate in a feedback cycle in which obesity promotes mitochondrial abnormalities while impaired mitochondrial metabolism further aggravates metabolic dysfunction.

8. Mitochondrial Dysfunction in Type 2 Diabetes

Type 2 diabetes is characterized by insulin resistance and progressive impairment of pancreatic β-cell function.

Mitochondria are central to glucose-stimulated insulin secretion in pancreatic β-cells.

Alterations in mitochondrial ATP generation can impair the cellular signals required for insulin release.

In skeletal muscle, mitochondrial dysfunction may reduce fatty-acid oxidation and alter glucose utilization.

Persistent hyperglycemia can further increase oxidative stress and mitochondrial damage.

Consequently, mitochondrial dysfunction may contribute to both the development and progression of type 2 diabetes.

9. Mitochondrial Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease

The liver is a major metabolic organ and contains a high density of mitochondria.

Mitochondria are essential for hepatic fatty-acid oxidation and energy metabolism.

Excessive lipid accumulation can increase mitochondrial oxidative stress and impair respiratory-chain function.

Damaged mitochondria may produce excessive ROS, activate inflammatory pathways, and contribute to hepatocellular injury.

Impaired mitochondrial quality control can further increase accumulation of dysfunctional organelles.

These mechanisms may contribute to the progression from hepatic steatosis to inflammatory and fibrotic liver disease.

10. Mitochondrial Dysfunction and Cardiovascular Disease

Cardiac muscle has exceptionally high energy requirements and depends heavily on mitochondrial oxidative phosphorylation.

Mitochondrial dysfunction can reduce ATP availability and increase oxidative stress in cardiomyocytes.

Endothelial mitochondrial dysfunction may also promote oxidative stress and vascular inflammation.

In atherosclerosis, mitochondrial abnormalities in vascular and immune cells may influence inflammatory responses and lipid metabolism.

Mitochondrial dysfunction has therefore been investigated as an important contributor to hypertension, atherosclerosis, ischemic heart disease, and heart failure.

11. Mitochondrial Dysfunction in Neurodegenerative Disorders

Neurons have high energy requirements and depend heavily on mitochondrial function.

Mitochondria supply ATP required for:

• Maintenance of membrane potential
• Neurotransmitter release
• Axonal transport
• Synaptic transmission
• Calcium regulation
• Neuronal survival

Because neurons have long axons and complex branching structures, appropriate mitochondrial distribution is essential.

Defects in mitochondrial transport, quality control, energy production, and calcium regulation can therefore have severe consequences.

Mitochondrial dysfunction has been implicated in Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and other neurodegenerative disorders.

12. Mitochondrial Dysfunction in Alzheimer's Disease

Alzheimer's disease is characterized by progressive cognitive decline and pathological changes involving amyloid-β accumulation, tau pathology, neuroinflammation, and neuronal loss.

Mitochondrial abnormalities have been observed in affected neurons and brain tissues.

Possible mechanisms include impaired electron transport chain activity, increased oxidative stress, disrupted mitochondrial trafficking, impaired mitophagy, and abnormal calcium handling.

Amyloid and tau-associated cellular stress may further disrupt mitochondrial function.

A vicious cycle may consequently develop in which mitochondrial dysfunction promotes oxidative stress and neuronal injury, while pathological protein accumulation further impairs mitochondria.

13. Mitochondrial Dysfunction in Parkinson's Disease

Parkinson's disease is characterized by progressive degeneration of dopaminergic neurons in specific regions of the brain.

Mitochondrial dysfunction has been strongly implicated in disease pathogenesis.

Complex I abnormalities, oxidative stress, impaired mitophagy, and altered mitochondrial dynamics have all been investigated in Parkinson's disease.

The PINK1 and Parkin proteins are particularly important because mutations affecting these proteins can disrupt mitochondrial quality control and are associated with inherited forms of Parkinsonian disease.

Accumulation of damaged mitochondria may contribute to neuronal vulnerability and progressive degeneration.

14. Mitochondrial Dysfunction in Huntington's Disease

Huntington's disease is caused by an inherited mutation affecting the huntingtin gene.

Mitochondrial abnormalities have been observed in affected neuronal populations.

Potential mechanisms include impaired respiratory-chain activity, altered mitochondrial transport, defective calcium regulation, and oxidative stress.

Mutant huntingtin can interfere with cellular pathways involved in mitochondrial maintenance and energy metabolism.

Progressive mitochondrial dysfunction may therefore contribute to neuronal degeneration in Huntington's disease.

15. Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis

Amyotrophic lateral sclerosis is a progressive neurodegenerative disease characterized by loss of motor neurons.

Mitochondrial abnormalities may contribute to motor-neuron vulnerability through impaired energy production, oxidative stress, altered mitochondrial transport, and defective quality control.

Motor neurons have extensive axonal structures and high metabolic requirements, making them particularly dependent on effective mitochondrial distribution.

Mitochondrial dysfunction may interact with protein aggregation, neuroinflammation, and excitotoxicity to accelerate neuronal injury.

16. Mitochondrial Calcium Homeostasis

Mitochondria participate in intracellular calcium regulation.

Controlled calcium uptake can stimulate metabolic activity and ATP production.

However, excessive mitochondrial calcium accumulation can trigger permeability-transition mechanisms and promote apoptosis or necrotic cell death.

Abnormal calcium handling is particularly important in neurons and cardiomyocytes.

Mitochondrial calcium dysregulation may therefore contribute to neurodegeneration, ischemic injury, and cardiac dysfunction.

17. Mitochondrial Dysfunction, Inflammation, and Immune Signaling

Mitochondria interact closely with innate immune signaling.

Damaged mitochondria can release mitochondrial DNA, ATP, cardiolipin, and other molecules capable of activating inflammatory pathways.

Mitochondrial stress can influence inflammasome activation and cytokine production.

This creates an important connection between mitochondrial dysfunction and chronic inflammation.

Persistent inflammatory signaling can further damage mitochondria, generating a feedback loop between mitochondrial injury and inflammation.

18. Materials and Methods

Review Design

The present article was developed as a narrative review examining the molecular mechanisms of mitochondrial dysfunction and its involvement in metabolic and neurodegenerative disorders.

Literature Search

Relevant scientific literature was examined using biomedical databases and peer-reviewed scientific journals.

Search terms included combinations of:

“Mitochondrial dysfunction,” “mitochondria,” “oxidative phosphorylation,” “oxidative stress,” “mitochondrial DNA,” “mitophagy,” “mitochondrial dynamics,” “mitochondrial biogenesis,” “metabolic disease,” “obesity,” “diabetes,” “metabolic liver disease,” “cardiovascular disease,” “Alzheimer's disease,” “Parkinson's disease,” “Huntington's disease,” and “amyotrophic lateral sclerosis.”

Inclusion Criteria

Studies were considered relevant when they:

1. Investigated mitochondrial structure or function;
2. Examined mitochondrial dysfunction in human disease;
3. Investigated metabolic disorders;
4. Examined neurodegenerative diseases;
5. Investigated mitochondrial quality control;
6. Examined oxidative stress or mitochondrial signaling; or
7. Evaluated potential mitochondrial therapeutic approaches.

Exclusion Criteria

Studies without substantial relevance to mitochondrial biology, metabolic disease, neurodegeneration, or mitochondrial therapeutic strategies were excluded from the main synthesis.

Data Synthesis

The available evidence was organized into major categories covering mitochondrial bioenergetics, oxidative stress, mitochondrial dynamics, mitophagy, mitochondrial biogenesis, metabolic disease, neurodegeneration, and therapeutic strategies.

19. Results

The reviewed literature demonstrates that mitochondrial dysfunction represents an important molecular mechanism connecting metabolic disturbances with cellular injury.

Several major findings emerged.

First, impaired oxidative phosphorylation can reduce ATP production and increase reactive oxygen species generation.

Second, mitochondrial DNA damage and impaired mitochondrial quality control can promote the accumulation of dysfunctional mitochondria.

Third, abnormal mitochondrial dynamics and defective mitophagy can contribute to progressive mitochondrial deterioration.

Fourth, metabolic diseases including obesity, insulin resistance, type 2 diabetes, fatty liver disease, and cardiovascular disorders are associated with mitochondrial abnormalities.

Fifth, neuronal tissues are particularly sensitive to mitochondrial dysfunction because of their high energy requirements and dependence on mitochondrial transport and calcium regulation.

Sixth, mitochondrial abnormalities have been implicated in major neurodegenerative disorders including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.

Finally, mitochondrial quality-control pathways, oxidative stress, mitochondrial biogenesis, and metabolic signaling represent potential therapeutic targets.

20. Therapeutic Perspectives

Exercise

Regular physical activity is one of the most effective physiological approaches for improving mitochondrial function.

Exercise can stimulate mitochondrial biogenesis, enhance oxidative capacity, improve insulin sensitivity, and strengthen antioxidant defenses.

Activation of AMPK and PGC-1α pathways contributes to many of these adaptations.

Exercise may therefore provide benefits across both metabolic and neurodegenerative disease contexts.

Nutritional Interventions

Nutritional status strongly influences mitochondrial metabolism.

Balanced dietary patterns can reduce metabolic stress and improve mitochondrial substrate utilization.

Dietary approaches that regulate caloric intake, improve metabolic flexibility, and reduce excessive lipid accumulation may support mitochondrial function.

Nutrient-sensitive pathways involving AMPK, mTOR, and sirtuins represent important molecular links between diet and mitochondrial biology.

Mitochondrial Antioxidants

Mitochondria-targeted antioxidants have been developed to reduce oxidative damage directly within mitochondria.

Unlike conventional antioxidants, targeted compounds are designed to accumulate preferentially within mitochondria.

Although preclinical findings are encouraging, clinical results have varied depending on the disease and therapeutic approach.

Enhancing Mitophagy

Because damaged mitochondria can accumulate during aging and disease, improving mitophagy represents a potential therapeutic strategy.

Activation of endogenous mitochondrial quality-control pathways may reduce oxidative stress and improve cellular energy metabolism.

However, excessive mitochondrial degradation may also be harmful, indicating that therapeutic modulation must maintain an appropriate balance.

Promoting Mitochondrial Biogenesis

Enhancing mitochondrial biogenesis may increase the cellular capacity to replace damaged organelles.

Potential targets include PGC-1α, AMPK, and sirtuin-associated pathways.

Pharmacological approaches that stimulate these pathways are under investigation for metabolic and neurodegenerative disorders.

Mitochondrial Replacement and Gene-Based Approaches

Inherited mitochondrial disorders can result from mutations in mitochondrial or nuclear genes.

Gene-based strategies and mitochondrial replacement approaches are being developed to address selected forms of mitochondrial disease.

Although these approaches remain technically challenging, advances in molecular medicine may expand their clinical applications.

Mitochondrial dysfunction represents a central feature of many chronic diseases because mitochondria occupy a critical position at the intersection of energy metabolism, oxidative stress, inflammation, and cell survival.

The relationship between mitochondrial dysfunction and metabolic disease is particularly complex.

Excess nutrient availability can increase metabolic pressure on mitochondria. At the same time, mitochondrial impairment can reduce the ability of cells to oxidize substrates efficiently. This can lead to accumulation of lipid intermediates, oxidative stress, and inflammatory signaling.

In type 2 diabetes, mitochondrial dysfunction can influence both insulin-sensitive tissues and pancreatic β-cells. Impaired mitochondrial ATP production may interfere with insulin secretion, while mitochondrial oxidative stress can contribute to cellular damage.

The brain presents another important example. Neurons have high energy requirements and limited regenerative capacity. Consequently, even moderate mitochondrial abnormalities may produce substantial functional consequences.

In Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders, mitochondrial dysfunction interacts with protein aggregation, oxidative stress, inflammation, calcium dysregulation, and impaired autophagy.

Mitochondrial quality control is therefore particularly important. Healthy cells must continuously balance mitochondrial biogenesis, fusion, fission, and mitophagy.

When this balance is disrupted, damaged mitochondria accumulate and may become persistent sources of ROS and inflammatory signals.

An important feature of mitochondrial dysfunction is its potential to establish self-reinforcing pathological cycles. For example, mitochondrial damage can increase ROS production, which can damage mitochondrial DNA and respiratory-chain proteins. Further respiratory dysfunction then increases oxidative stress.

Similarly, damaged mitochondria can activate inflammatory signaling, while inflammatory mediators can further impair mitochondrial function.

These feedback loops may help explain why mitochondrial abnormalities become increasingly difficult to reverse during chronic disease progression.

Despite substantial evidence, several important questions remain. It is often difficult to determine whether mitochondrial dysfunction is a primary cause of disease or a secondary consequence of other pathological processes.

Furthermore, mitochondrial responses vary between tissues and disease stages. A moderate increase in mitochondrial activity may be adaptive in one context but harmful under another.

Consequently, therapeutic approaches should focus on restoring mitochondrial homeostasis rather than simply increasing or decreasing mitochondrial activity.

22. Future Perspectives

Future mitochondrial research should focus on developing precise methods for identifying dysfunctional mitochondrial populations in specific tissues.

Single-cell sequencing, spatial molecular profiling, advanced imaging, metabolomics, and proteomics may help determine how mitochondrial dysfunction differs among cell types.

Another major research priority is understanding the relationship between mitochondrial dysfunction and aging.

Because mitochondrial quality-control systems decline with age, interventions that maintain mitochondrial turnover and metabolic flexibility may have broad applications.

The development of mitochondria-targeted drugs may also improve therapeutic specificity.

Future treatments may combine approaches that reduce oxidative stress, enhance mitophagy, stimulate mitochondrial biogenesis, and regulate metabolic signaling.

Personalized mitochondrial medicine may eventually allow treatment strategies to be selected according to an individual's mitochondrial genotype, metabolic profile, disease stage, and tissue-specific mitochondrial abnormalities.

Mitochondrial dysfunction is an important molecular mechanism involved in the development and progression of metabolic and neurodegenerative disorders.

Mitochondria regulate ATP production, oxidative metabolism, calcium homeostasis, reactive oxygen species signaling, apoptosis, and immune responses. Disruption of these functions can lead to cellular energy deficiency, oxidative stress, inflammation, and tissue injury.

In metabolic disorders, mitochondrial dysfunction contributes to obesity, insulin resistance, type 2 diabetes, fatty liver disease, and cardiovascular complications. In the nervous system, mitochondrial abnormalities are strongly associated with Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and other neurodegenerative conditions.

Major mechanisms include impaired oxidative phosphorylation, mitochondrial DNA damage, abnormal mitochondrial dynamics, defective mitophagy, impaired mitochondrial biogenesis, calcium dysregulation, and excessive reactive oxygen species production.

Therapeutic approaches targeting mitochondrial dysfunction include exercise, nutritional interventions, mitochondrial antioxidants, enhancement of mitophagy, stimulation of mitochondrial biogenesis, metabolic modulation, and emerging gene-based approaches.

A deeper understanding of mitochondrial biology and tissue-specific mitochondrial responses may facilitate the development of more precise therapeutic strategies. Maintaining mitochondrial quality and restoring metabolic homeostasis may ultimately provide important opportunities for preventing or treating chronic metabolic and neurodegenerative diseases.

1. Wallace DC. Mitochondrial diseases in man and mouse. Science. 1999;283:1482–1488.
2. Nunnari J, Suomalainen A. Mitochondria: in sickness and in health. Cell. 2012;148:1145–1159.
3. Friedman JR, Nunnari J. Mitochondrial form and function. Nature. 2014;505:335–343.
4. Spinelli JB, Haigis MC. The multifaceted contributions of mitochondria to cellular metabolism. Nature Cell Biology. 2018;20:745–754.
5. Murphy MP. How mitochondria produce reactive oxygen species. Biochemical Journal. 2009;417:1–13.
6. Brand MD. The sites and topology of mitochondrial superoxide production. Experimental Gerontology. 2010;45:466–472.
7. Youle RJ, Narendra DP. Mechanisms of mitophagy. Nature Reviews Molecular Cell Biology. 2011;12:9–14.
8. Pickles S, Vigié P, Youle RJ. Mitophagy and quality control mechanisms in mitochondrial maintenance. Current Biology. 2018;28:R170–R185.
9. Chan DC. Mitochondrial dynamics and its involvement in disease. Annual Review of Pathology. 2020;15:235–259.
10. Youle RJ, van der Bliek AM. Mitochondrial fission, fusion, and stress. Science. 2012;337:1062–1065.
11. Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochimica et Biophysica Acta. 2011;1813:1269–1278.
12. Jastroch M, Divakaruni AS, Mookerjee S, Treberg JR, Brand MD. Mitochondrial proton and electron leaks. Essays in Biochemistry. 2010;47:53–67.
13. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science. 2005;307:384–387.
14. Patti ME, Corvera S. The role of mitochondria in the pathogenesis of type 2 diabetes. Endocrine Reviews. 2010;31:364–395.
15. Petersen KF, Befroy D, Dufour S, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science. 2003;300:1140–1142.
16. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature. 2006;443:787–795.
17. Schon EA, Przedborski S. Mitochondria: the next therapeutic frontier in Parkinson's disease. Nature Medicine. 2011;17:251–253.
18. Johri A, Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. Journal of Pharmacology and Experimental Therapeutics. 2012;342:619–630.
19. Area-Gomez E, Schon EA. Mitochondrial genetics and disease. Cold Spring Harbor Perspectives in Biology. 2014;6:a014003.
20. Wang W, Karamanlidis G, Tian R. Genetic deficiency in phospholipid remodeling causes cardiolipin loss and mitochondrial dysfunction. Nature Medicine. 2013;19:1–7.
21. Schrepfer E, Scorrano L. Mitofusins, from mitochondria to metabolism. Molecular Cell. 2016;61:683–694.
22. Dorn GW, Vega RB, Kelly DP. Mitochondrial biogenesis and dynamics in the developing and diseased heart. Genes & Development. 2015;29:1–11.
23. Picard M, McEwen BS, Epel ES, Sandi C. An energetic view of stress: focus on mitochondria. Frontiers in Neuroendocrinology. 2018;49:72–85.
24. Swerdlow RH. Mitochondria and mitochondrial cascades in Alzheimer's disease. Journal of Alzheimer's Disease. 2018;62:1403–1416.Tait SWG, Green DR. Mitochondria and cell signalling. Journal of Cell Science. 2012;125:807–815